Peterson Amy C.
Insider CIK 1682735 · CTMX EVP, Chief Development Officer · BGNE CMO, Immuno-oncology · EXEL EVP Prod Dev & Med Aff & CMO
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| EXEL EXELIXIS, INC. | M Exercise deriv | 2025-05-16 | 2025-05-16 | 40,000 | — | $0 | 120,000 | SEC↗ |
| EXEL EXELIXIS, INC. | M Exercise | 2025-05-16 | 2025-05-16 | 40,000 | $21.75 | $870.0K | 538,169 | SEC↗ |
| EXEL EXELIXIS, INC. | S Sale | 2025-05-16 | 2025-05-16 | 72,776 | $45.47 | $3.31M | 465,393 | SEC↗ |
| EXEL EXELIXIS, INC. | F Tax w/h | 2025-05-15 | 2025-05-16 | 8,303 | $44.65 | $370.7K | 498,169 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award | 2025-03-31 | 2025-03-31 | 159,383 | — | $0 | 506,472 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award | 2025-02-26 | 2025-02-28 | 52,192 | — | $0 | 347,089 | SEC↗ |
| EXEL EXELIXIS, INC. | F Tax w/h | 2024-11-15 | 2024-11-19 | 27,224 | $35.05 | $954.2K | 294,897 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award | 2024-02-23 | 2024-02-27 | 82,121 | — | $0 | 322,121 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award deriv | 2023-08-24 | 2023-08-25 | 160,000 | — | $0 | 160,000 | SEC↗ |
| EXEL EXELIXIS, INC. | A Award | 2023-08-24 | 2023-08-25 | 240,000 | — | $0 | 240,000 | SEC↗ |
| CTMX CytomX Therapeutics, Inc. | S Sale | 2023-03-16 | 2023-03-20 | 4,257 | $1.98 | $8.4K | 58,433 | SEC↗ |
| CTMX CytomX Therapeutics, Inc. | S Sale | 2022-07-20 | 2022-07-21 | 7,463 | $1.42 | $10.6K | 62,690 | SEC↗ |
| CTMX CytomX Therapeutics, Inc. | A Award | 2022-07-19 | 2022-07-21 | 20,000 | — | $0 | 70,153 | SEC↗ |
| CTMX CytomX Therapeutics, Inc. | A Award deriv | 2022-02-02 | 2022-02-04 | 200,000 | — | $0 | 200,000 | SEC↗ |
| CTMX CytomX Therapeutics, Inc. | A Award | 2022-02-02 | 2022-02-04 | 40,000 | — | $0 | 46,421 | SEC↗ |
| CTMX CytomX Therapeutics, Inc. | A Award deriv | 2021-10-24 | 2021-10-26 | 40,000 | — | $0 | 40,000 | SEC↗ |
| CTMX CytomX Therapeutics, Inc. | A Award deriv | 2021-10-24 | 2021-10-26 | 50,000 | — | $0 | 50,000 | SEC↗ |
| CTMX CytomX Therapeutics, Inc. | A Award | 2021-05-31 | 2021-06-08 | 3,320 | $6.09 | $20.2K | 6,421 | SEC↗ |
| CTMX CytomX Therapeutics, Inc. | A Award deriv | 2021-02-26 | 2021-03-02 | 250,000 | — | $0 | 250,000 | SEC↗ |
| CTMX CytomX Therapeutics, Inc. | A Award | 2020-11-30 | 2020-12-07 | 3,101 | $6.39 | $19.8K | 3,101 | SEC↗ |
| CTMX CytomX Therapeutics, Inc. | A Award deriv | 2020-02-14 | 2020-02-19 | 25,000 | — | $0 | 25,000 | SEC↗ |
| CTMX CytomX Therapeutics, Inc. | A Award deriv | 2019-10-15 | 2019-10-16 | 400,000 | — | $0 | 400,000 | SEC↗ |
| BGNE BeiGene, Ltd. | M Exercise deriv | 2018-12-18 | 2018-12-19 | 131,833 | — | $0 | 820,000 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-12-18 | 2018-12-19 | 611 | $135.54 | $82.8K | 0 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-12-18 | 2018-12-19 | 3,600 | $134.81 | $485.3K | 611 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-12-18 | 2018-12-19 | 2,402 | $133.88 | $321.6K | 4,211 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-12-18 | 2018-12-19 | 1,897 | $132.70 | $251.7K | 6,613 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-12-18 | 2018-12-19 | 1,631 | $131.74 | $214.9K | 8,510 | SEC↗ |
| BGNE BeiGene, Ltd. | M Exercise | 2018-12-18 | 2018-12-19 | 10,141 | $29.10 | $295.1K | 10,141 | SEC↗ |
| BGNE BeiGene, Ltd. | M Exercise deriv | 2018-12-17 | 2018-12-19 | 128,167 | — | $0 | 951,833 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-12-17 | 2018-12-19 | 2,296 | $136.24 | $312.8K | 480 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-12-17 | 2018-12-19 | 778 | $135.04 | $105.1K | 2,776 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-12-17 | 2018-12-19 | 1,005 | $133.81 | $134.5K | 3,554 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-12-17 | 2018-12-19 | 1,700 | $132.91 | $225.9K | 4,559 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-12-17 | 2018-12-19 | 2,700 | $131.80 | $355.9K | 6,259 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-12-17 | 2018-12-19 | 900 | $130.37 | $117.3K | 8,959 | SEC↗ |
| BGNE BeiGene, Ltd. | M Exercise | 2018-12-17 | 2018-12-19 | 9,859 | $29.10 | $286.9K | 9,859 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-12-17 | 2018-12-19 | 480 | $136.93 | $65.7K | 0 | SEC↗ |
| BGNE BeiGene, Ltd. | M Exercise deriv | 2018-11-12 | 2018-11-13 | 156,871 | — | $0 | 1,080,000 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-12 | 2018-11-13 | 100 | $121.56 | $12.2K | 0 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-12 | 2018-11-13 | 109 | $117.61 | $12.8K | 100 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-12 | 2018-11-13 | 500 | $116.56 | $58.3K | 209 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-12 | 2018-11-13 | 700 | $114.96 | $80.5K | 709 | SEC↗ |
| BGNE BeiGene, Ltd. | M Exercise | 2018-11-12 | 2018-11-13 | 12,067 | $29.10 | $351.1K | 12,067 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-12 | 2018-11-13 | 2,958 | $111.10 | $328.6K | 9,109 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-12 | 2018-11-13 | 4,000 | $112.18 | $448.7K | 5,109 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-12 | 2018-11-13 | 2,527 | $113.03 | $285.6K | 2,582 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-12 | 2018-11-13 | 1,173 | $113.92 | $133.6K | 1,409 | SEC↗ |
| BGNE BeiGene, Ltd. | M Exercise deriv | 2018-11-09 | 2018-11-13 | 171,886 | — | $0 | 1,236,871 | SEC↗ |
| BGNE BeiGene, Ltd. | M Exercise | 2018-11-09 | 2018-11-13 | 13,222 | $29.10 | $384.8K | 13,222 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-09 | 2018-11-13 | 4,031 | $118.64 | $478.2K | 9,191 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-09 | 2018-11-13 | 1,725 | $119.27 | $205.7K | 7,466 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-09 | 2018-11-13 | 2,100 | $120.63 | $253.3K | 5,366 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-09 | 2018-11-13 | 2,898 | $121.71 | $352.7K | 2,468 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-09 | 2018-11-13 | 2,046 | $122.55 | $250.7K | 422 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-09 | 2018-11-13 | 322 | $123.75 | $39.8K | 100 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-09 | 2018-11-13 | 100 | $125.97 | $12.6K | 0 | SEC↗ |
| BGNE BeiGene, Ltd. | M Exercise deriv | 2018-11-08 | 2018-11-13 | 191,243 | — | $0 | 1,408,757 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-08 | 2018-11-13 | 200 | $127.61 | $25.5K | 0 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-08 | 2018-11-13 | 7,673 | $126.72 | $972.3K | 200 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-08 | 2018-11-13 | 3,949 | $126.08 | $497.9K | 7,873 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-08 | 2018-11-13 | 2,423 | $124.48 | $301.6K | 11,822 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-11-08 | 2018-11-13 | 466 | $122.86 | $57.3K | 14,245 | SEC↗ |
| BGNE BeiGene, Ltd. | M Exercise | 2018-11-08 | 2018-11-13 | 14,711 | $29.10 | $428.1K | 14,711 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-08-23 | 2018-08-24 | 2,300 | $168.94 | $388.6K | 2,361 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-08-23 | 2018-08-24 | 961 | $170.46 | $163.8K | 0 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-08-23 | 2018-08-24 | 1,400 | $169.75 | $237.7K | 961 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2018-08-23 | 2018-08-24 | 1,108 | $167.54 | $185.6K | 4,661 | SEC↗ |
| BGNE BeiGene, Ltd. | A Award deriv | 2018-06-26 | 2018-06-28 | 310,180 | — | $0 | 310,180 | SEC↗ |
| BGNE BeiGene, Ltd. | A Award | 2018-06-26 | 2018-06-28 | 44,564 | — | $0 | 269,566 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2017-11-13 | 2017-11-15 | 1,201 | $83.31 | $100.1K | 0 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2017-11-13 | 2017-11-15 | 2,400 | $82.79 | $198.7K | 1,201 | SEC↗ |
| BGNE BeiGene, Ltd. | F Tax w/h | 2017-08-22 | 2017-08-24 | 28,185 | $5.39 | $151.9K | 271,815 | SEC↗ |
| BGNE BeiGene, Ltd. | A Award deriv | 2017-06-27 | 2017-06-29 | 1,016,178 | — | $0 | 1,016,178 | SEC↗ |
| BGNE BeiGene, Ltd. | A Award deriv | 2016-08-22 | 2016-08-24 | 1,600,000 | — | $0 | 1,600,000 | SEC↗ |
| BGNE BeiGene, Ltd. | A Award | 2016-08-22 | 2016-08-24 | 300,000 | — | $0 | 300,000 | SEC↗ |